.png)
OBJECTIVE: The aim of this study was to determine the prevalence and the characteristics of coronavirus disease 2019 (COVID-19) in a tertiary outpatient clinic of asthma patients, find the predisposing asthma phenotype to COVID-19, and to see their adherence to asthma treatment.
MATERIAL AND METHODS: A retrospective, cross-sectional, real life study was conducted via phone interviews with the patients being followed in the asthma outpatient clinic. From the files of the patient information was obtained about their demographics, asthma phenotype, co-morbidity, prick tests, spirometry test results and their medications at the last visit before the COVID-19 pandemic. Information’s about asthma exacerbations, ACT, asthma treatment adherence and history of COVID-19 were obtained via telephone interviews.
RESULTS: Of the 573 patients with asthma, 13 (2.26%) had COVID-19 history. The mean age of patients with asthma and COVID-19 was 51.84±14.92 year. Two patients were on mepolizumab and one was on omalizumab treatment. Mean ACT was 19.84±2.73. Lack of adherence was reported in 8% of all patients with asthma compared to 23% in the patients who had COVID-19. Asthma exacerbation was seen during the course of SARS-CoV2 infection in 3 of 13 patients with asthma. Asthma exacerbations were reported during the period of one month following COVID-19 in 2 patients.
CONCLUSION: The most common asthma phenotype in the cases of COVID-19 was obese phenotype. Rates of using biological agents and non-adherence to the treatment were found to be higher. Asthma exacerbation may be seen during course of COVID-19 albeit being less common.
Cite this article as: Çalışkaner Öztürk B, Güngördü Mazıcan N, Çalışkan EB, Tuz AA, Gemicioğlu B. Coronavirus disease 2019 in patients with asthma: Case study from a tertiary center regarding their phenotypes and their adherence to asthma treatment by telemedicine. Turk Thorac J. 2022;23(1):25-31.